Floatz logo

Docetaxel

Carcinoma

Merck Sharp & Dohme LLCSmall moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
AstraZeneca
Phase 4BB
Crizotinib
Ariad Pharmaceuticals
Phase 3BB
ALBUMIN AGGREGATED
Sirtex Medical
Phase 4BB
Osimertinib
AstraZeneca
Phase 3BB
Trebananib
Amgen
Phase 2BB

View all 50 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →